TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04427592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of uterine wall defect
Description: uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
Study: NCT00693381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study: NCT02919956

Intervention type: OTHER
Intervention: Neurodevelopmental Testing
Description: Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.

Intervention type: OTHER
Intervention: Neurodevelopmental Testing
Description: Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.

Intervention type: OTHER
Intervention: Neurodevelopmental Testing
Description: Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
Study: NCT04483596

Intervention type: DRUG
Intervention: melatonin effect on the Abbreviated Mental Test
Description: Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1

Intervention type: DRUG
Intervention: melatonin effect on the Abbreviated Mental Test
Description: Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1
Study: NCT02614898

Intervention type: OTHER
Intervention: Eculizumab
Description: This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
Study: NCT02075385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre, during and pos-treatment swallowing exercises
Description: Speech pathology therapy
Study: NCT04429971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP screening program
Description: ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
Study: NCT02919956

Intervention type: OTHER
Intervention: Neurodevelopmental Testing
Description: Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
Study: NCT01664650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00606658

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shirodhara Oil Treatment
Description: Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
Study: NCT01325740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STX107
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX107
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX107
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
Study: NCT03544216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Contact Lens
Description: The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Contact Lens
Description: The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Vision Contact Lens
Description: The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Vision Contact Lens
Description: The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
Study: NCT04600635

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
Study: NCT02169323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step-down
Description: Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
Study: NCT02127216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: MOSES is an integrated system between a patient, peer patients, and healthcare providers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: MOSES is an integrated system between a patient, peer patients, and healthcare providers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: MOSES is an integrated system between a patient, peer patients, and healthcare providers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: MOSES is an integrated system between a patient, peer patients, and healthcare providers.
Study: NCT01023113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASCAL laser
Description: PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laser
Description: PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
Study: NCT01698736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Membrane filtration
Description: Membrane filtration (Polysulfone)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semiselective IA
Description: Semiselective immunoadsorption (GAM peptide adsorber)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semiselective IA
Description: Semiselective immunoadsorption (GAM peptide adsorber)
Study: NCT01049464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
Study: NCT02784236

Intervention type: DEVICE
Group type: OTHER
Intervention: telemedicine
Description: The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
Study: NCT00673660

Intervention type: BEHAVIORAL
Intervention: Patient Compliance
Description: Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
Study: NCT05762016

Intervention type: PROCEDURE
Intervention: Bedside Mini-Incision and Self-Express (MISE)
Description: To perform bedside mini incision and encourage patients to self express the pus following the intervention
Study: NCT03097692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic preconditioning
Description: ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacologic preconditionig
Description: Pharmacologic preconditionig will be attained by sevoflurane anesthesia
Study: NCT04429971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP screening program
Description: ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP screening program
Description: ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP starter pack
Description: emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
Study: NCT00292370

Intervention type: DRUG
Group type: OTHER
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label (OL) Paroxetine
Description: Open-label Paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo taken with OL paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Double-blind quetiapine taken with OL paroxetine
Study: NCT01435980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass
Description: basal treatment and Gastric Bypass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: basal treatment and Exenatide
Study: NCT01123525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Study: NCT04209803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5% topically and oral NAC 600 mg
Description: Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5% topically and oral NAC 600 mg
Description: Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil 5% topically and oral NAC 600 mg
Description: Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
Study: NCT02301429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 20105
Description: implant and follow-up of study device
Study: NCT02238327

Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
Study: NCT03785340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
Study: NCT01374451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
Study: NCT02238327

Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.

Intervention type: PROCEDURE
Intervention: questionnaires
Description: The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
Study: NCT01545349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Description: Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: 0.2 mL pre-filled, single use intranasal spray

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Live attenuated influenza vaccine
Description: 0.2 mL pre-filled, single use intranasal spray
Study: NCT01305109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORV 116E
Description: Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of 0.5 mL at 4 week intervals
Study: NCT02125149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study: NCT01859637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
Study: NCT00978536

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive impairment of multiple sclerosis
Description: Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive impairment of multiple sclerosis
Description: Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive impairment of multiple sclerosis
Description: Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
Study: NCT02431949

Intervention type: OTHER
Intervention: Admission to BCPP
Description: There is no intervention associated with this study.
Study: NCT03685409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin hydrochloride tablets 500 mg given orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch Placebo oral tablets will be given once daily to the control group
Study: NCT02658214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (paclitaxel-albumin) + carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
Description: IV infusion and bolus administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion
Study: NCT02238327

Intervention type: PROCEDURE
Intervention: questionnaires
Description: The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
Study: NCT00693381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone and prednisone
Description: IV and oral
Study: NCT02238327

Intervention type: PROCEDURE
Intervention: Lung function testing
Description: The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.

Intervention type: PROCEDURE
Intervention: Lung function testing
Description: The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.

Intervention type: PROCEDURE
Intervention: Six-Minute walk test
Description: Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
Study: NCT00693381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone and prednisone
Description: IV and oral
Study: NCT02658214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (paclitaxel-albumin) + gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + 5-fluorouracil (5FU)
Description: IV infusion
Study: NCT01015287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study: NCT04440150

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Open or Laparascopic Surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Open or Laparascopic Surgery